Gastroesophageal Reflux Disease (GERD): Overview and Management
Definition and Clinical Presentation
GERD is a condition that develops when reflux of stomach contents causes troublesome symptoms and/or complications that adversely affect an individual's well-being. 1 The disease manifests primarily through heartburn and regurgitation, though atypical presentations including chest pain, chronic cough, and laryngeal symptoms can occur. 2, 3
The condition is subdivided into symptomatic syndromes and syndromes with esophageal injury (erosive esophagitis, Barrett's esophagus), with non-erosive reflux disease representing the most common phenotype. 4 Importantly, functional heartburn—where symptoms occur without objective evidence of pathologic reflux—does not meet the definition of GERD. 1
Lifestyle Modifications
Weight loss should be advised for overweight or obese patients with GERD, as this is the only lifestyle modification with Grade B evidence supporting its effectiveness. 1
Other lifestyle modifications should be tailored to individual patient circumstances rather than broadly applied to all patients: 1
- Elevation of the head of the bed is recommended specifically for patients troubled with nighttime heartburn or regurgitation despite acid suppressive therapy 1
- Avoidance of specific trigger foods (coffee, alcohol, chocolate, fatty foods, citrus, carbonated drinks, spicy foods) should be recommended only when patients consistently experience symptoms after ingestion of these items 1
- Avoiding recumbency for 2-3 hours after meals and avoiding late meals may benefit select patients 1
- Smoking cessation should be advised as part of reducing esophageal acid exposure 1
The evidence does not support broadly advocating all lifestyle changes to every GERD patient (Grade Insufficient), as each modification is too narrowly applicable. 1
Pharmacologic Treatment Approach
Initial Empirical Therapy
For patients presenting with typical reflux symptoms (heartburn, regurgitation, non-cardiac chest pain) without alarm symptoms, a 4-8 week trial of single-dose proton pump inhibitor (PPI) therapy is appropriate and safe. 2 This empirical approach is recommended before pursuing diagnostic testing in uncomplicated cases. 1
PPI Efficacy and Dosing
PPIs are more effective than H2-receptor antagonists (H2RAs), which are more effective than placebo, for both healing esophagitis and providing symptomatic relief (Grade A evidence). 1
The dosing algorithm should follow this sequence: 2, 5
- Start with once-daily PPI for 4-8 weeks
- If inadequate response, increase to twice-daily dosing or switch to a more potent acid suppressive agent 2
- Once adequate response is achieved, titrate to the lowest effective dose 2
- Twice-daily PPI dosing should be considered treatment failure if symptoms persist, making this a reasonable upper limit for empirical therapy before pursuing diagnostic evaluation 1
Important Caveat on PPI Safety
Clinicians should emphasize the safety of PPIs for GERD treatment to patients. 2 Despite publications raising concerns about adverse events with long-term use, PPIs remain the medical treatment of choice and should be used at the lowest dose for the shortest duration necessary while discussing long-term management options. 6, 5
Adjunctive Pharmacologic Options
H2RAs as bedtime add-on therapy are suggested only for patients with persistent nocturnal symptoms and objective evidence of nocturnal acid reflux on pH monitoring despite PPI treatment. 7
Prokinetic agents may be considered as add-on therapy in patients with concomitant symptoms suggesting delayed gastric emptying. 7 However, metoclopramide as monotherapy or adjunctive therapy is not recommended (Grade D) due to fair evidence that harms outweigh benefits. 1
Alginates and antacids can provide rapid symptom relief for on-demand therapy, particularly when onset of action is a priority. 1, 7
Neuromodulators (primarily antidepressants) and psychological interventions may benefit patients with functional disorders that overlap with or mimic GERD, particularly those with visceral hypersensitivity. 8, 7
When to Pursue Diagnostic Testing
Upper endoscopy is indicated in the following circumstances: 2, 6
- Presence of alarm symptoms (dysphagia, odynophagia, weight loss, gastrointestinal bleeding) 6
- Multiple risk factors for Barrett's esophagus 6
- Inadequate response to twice-daily PPI therapy 1
- Isolated extra-esophageal symptoms 2
- History of sleeve gastrectomy 6
Prolonged wireless pH monitoring off PPI therapy should be performed in patients without erosive disease on endoscopy to assess esophageal acid exposure and distinguish true GERD from functional esophageal disorders. 2 This testing is also recommended before considering anti-reflux surgical or endoscopic procedures. 7
Surgical and Endoscopic Interventions
For patients with confirmed GERD and small hiatal hernias (≤2 cm) with Hill grade I or II who meet specific criteria, transoral incisionless fundoplication (TIF) should be evaluated as an alternative to chronic medical management. 6
For patients with persistent GERD and large hiatal hernias (>2 cm) with Hill grade III or IV, either combined TIF with hiatal hernia repair (cTIF) or surgical therapy should be considered based on multidisciplinary review. 6
Laparoscopic fundoplication and magnetic sphincter augmentation are effective surgical options in patients with proven GERD. 2 In obese patients with proven GERD, Roux-en-Y gastric bypass is an effective primary anti-reflux intervention, while sleeve gastrectomy has potential to worsen GERD. 2
Candidacy for invasive anti-reflux procedures requires: 2
- Confirmatory evidence of pathologic GERD
- Exclusion of achalasia
- Assessment of esophageal peristaltic function
Patient Education and Shared Decision-Making
Clinicians should provide standardized educational material on GERD mechanisms, weight management, lifestyle and dietary behaviors, relaxation strategies, and the brain-gut axis relationship. 2 A care plan should be developed in a shared decision-making model that addresses investigation of symptoms, selection of therapy with explanation of risks and benefits, and long-term management including possible de-escalation. 2
Management of Refractory GERD
For patients not responding to optimized PPI therapy, a precision approach to escalation should be driven by: 2
- Integrity of the anti-reflux barrier
- Presence of visceral hypersensitivity and hypervigilance
- Confirmation of PPI-refractory GERD through objective testing
- Symptom profile and body mass index
- Esophageal and gastric motor function
Patients without erosive disease on endoscopy and with physiologic acid exposure often have a functional esophageal disorder, in which case neuromodulation or behavioral interventions can be utilized and PPI therapy can be titrated off as tolerated. 2